Jesper Høiland made a decision, and share prices fell by 17 percent: "That's just part of taking responsibility"

The former head of Novo Nordisk in the US disappointed investors when he decided to sell two cancer drug candidates under development at his company Radius Health. It is necessary to focus the business, the CEO says.

Jesper Høiland has been CEO of Radius Health since July 2017. Photo: Radius Health/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles